Claims for Patent: 10,172,905

Summary for Patent: 10,172,905

Title:	Treatment of protein degradation disorders
Abstract:	The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
Inventor(s):	Anderson; Kenneth C. (Wellesley, MA), Bradner; James E. (Weston, MA), Greenberg; Edward Franklin (Cleveland, OH), Hideshima; Teru (Brookline, MA), Kwiatkowski; Nicholas Paul (Brookline, MA), Mazitschek; Ralph (Belmont, MA), Schreiber; Stuart L. (Boston, MA), Shaw; Jared (Davis, CA), Haggarty; Stephen J. (Gloucester, MA)
Assignee:	President and Fellows of Harvard College (Cambridge, MA) Dana-Farber Cancer Institute, Inc. (Boston, MA)
Application Number:	15/401,902
Patent Claims:	1. A method of treating a subject suffering from ovarian cancer comprising administering to a subject in need thereof a therapeutically effective amount of a proteasome inhibitor and an aggresome inhibitor, wherein the aggresome inhibitor selectively inhibits HDAC6. 2. The method of claim 1, wherein the proteasome inhibitor is selected from the group consisting of bortezomib, MG 132, sapojargon, and NPI-0052. 3. The method of claim 1, wherein the aggresome inhibitor is of the formula: ##STR00073## or a pharmaceutically acceptable salt thereof, wherein R.sub.1 is cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; --OR.sub.A; --C(.dbd.O)R.sub.A; --CO.sub.2R.sub.A; --SR.sub.A; --SOR.sub.A; --SO.sub.2R.sub.A; --N(R.sub.A).sub.2; --NHC(O)R.sub.A; or --C(R.sub.A).sub.3; wherein each occurrence of R.sub.A is independently a hydrogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino; alkylamino; dialkylamino; heteroaryloxy; or heteroarylthio moiety; R.sub.2 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; --OR.sub.B; --C(.dbd.O)R.sub.B; --CO.sub.2R.sub.B; --CN; --SCN; --SR.sub.B; --SOR.sub.B; --SO.sub.2R.sub.B; --NO.sub.2; --N(R.sub.B).sub.2; --NHC(O)R.sub.B; or --C(R.sub.B).sub.3; wherein each occurrence of R.sub.B is independently a hydrogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino; alkylamino; dialkylamino; heteroaryloxy; or heteroarylthio moiety; and R.sub.3 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; --OR.sub.C; --C(.dbd.O)R.sub.C; --CO.sub.2R.sub.C; --CN; --SCN; --SR.sub.C; --SOR.sub.C; --SO.sub.2R.sub.C; --NO.sub.2; --N(R.sub.C).sub.2; --NHC(O)R.sub.C; or --C(R.sub.C).sub.3; wherein each occurrence of R.sub.C is independently a hydrogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino; alkylamino; dialkylamino; heteroaryloxy; or heteroarylthio moiety. 4. The method of claim 1, wherein the aggresome inhibitor is of the formula: ##STR00074## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is hydrogen, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; n is 1-5; R.sup.2 is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; X is --O--, --C(R.sup.2A).sub.2--, --S--, or --NR.sup.2A--, wherein R.sup.2A is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; or wherein two or more occurrences of R.sup.2 and R.sup.2A, taken together, form an alicyclic or heterocyclic moiety, or an aryl or heteroaryl moiety; R.sup.3 is an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or heteroaromatic moiety; and Y is hydrogen or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic, or heteroaromatic moiety. 5. The method of claim 1, wherein the aggresome inhibitor is selected from the group consisting of: ##STR00075## ##STR00076## and pharmaceutically acceptable salts thereof. 6. The method of claim 1, wherein the aggresome inhibitor is dynein. 7. The method of claim 1, further comprising administering a therapeutically effective amount of one or more additional protein degradation inhibitors to the subject. 8. The method of claim 7, wherein at least one of the additional protein degradation inhibitors is a proteasome inhibitor. 9. The method of claim 1, further comprising co-administering one or more of a chemotherapeutic agent, radiation agent, hormonal agent, biological agent, or anti-inflammatory agent to the subject. 10. The method of claim 1, wherein the subject is a human. 11. The method of claim 1, wherein the aggresome inhibitor is the following: ##STR00077## or a pharmaceutically acceptable salt thereof. 12. The method of claim 1, wherein the aggresome inhibitor is of the following formula: ##STR00078## or a pharmaceutically acceptable salt thereof, wherein: each X is independently O, S, CH.sub.2, or NR.sub.3; Y is O, S, CH.sub.2, or NR.sub.4; Ar.sub.1 and Ar.sub.2 are each independently an aryl group; R.sub.1 is a lower alkyl group or an aryl group; R.sub.2 is hydrogen, a lower alkyl group, or an aryl group; and R.sub.3 is hydrogen, a lower alkyl group, an aryl group, an alkylcarbonyl, an alkoxycarbonyl group, or an aminocarbonyl group. 13. The method of claim 12, wherein: X is for both occurrences O; Y is S; Ar.sub.1 is phenyl or substituted phenyl; Ar.sub.2 is heteroaryl; R.sub.1 is phenyl or substituted phenyl; and R.sub.2 is hydrogen. 14. The method of claim 12, wherein: X is for both occurrences O; Y is S; Ar.sub.1 is phenyl or substituted phenyl; Ar.sub.2 is optionally substituted oxazolyl; R.sub.1 is 4-aminosubstituted phenyl; and R.sub.2 is hydrogen. 15. The method of claim 1, wherein the aggresome inhibitor inhibits the C-terminal aceylation activity of HDAC6, thereby inhibiting aggresome mediated protein degradation. 16. The method of claim 7, wherein at least one of the additional protein degradation inhibitors is an aggresome inhibitor. 17. The method of claim 1, further comprising obtaining a biological sample from a subject. 18. The method of claim 1, further comprising monitoring the treatment or progress of the subject. 19. The method of claim 9, wherein a chemotherapeutic is co-administered. 20. The method of claim 19, wherein the chemotherapeutic agent is tamoxifen, trastuzamab, raloxifene, doxorubicin, fluorouracil/5-fu, pamidronate disodium, anastrozole, exemestane, cyclophosphamide, epirubicin, letrozole, toremifene, fulvestrant, fluoxymesterone, trastuzumab, methotrexate, megastrol acetate, docetaxel, paclitaxel, testolactone, aziridine, vinblastine, capecitabine, goselerin acetate, zoledronic acid, taxol, or vincristine.

Details for Patent 10,172,905

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2025-03-22
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2025-03-22
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2025-03-22